Evidence map›Paper›PMID 34275909›Full record

ArticleJournal of Parkinson's disease2021

Choroidal Thickness Correlates with Clinical and Imaging Metrics of Parkinson's Disease: A Pilot Study.

Gregory L Brown, Mona L Camacci, Sean D Kim, Stephanie Grillo, James V Nguyen, Douglas A Brown, Sarah P Ullah, Mechelle M Lewis, Guangwei Du, Lan Kong and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Gregory L BrownDepartment of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Mona L CamacciDepartment of Ophthalmology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Sean D KimDepartment of Ophthalmology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Stephanie GrilloDepartment of Ophthalmology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
James V NguyenDepartment of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Douglas A BrownDepartment of Ophthalmology, Temple University-Lewis Katz School of Medicine, Philadelphia, PA, USA.
Sarah P UllahDepartment of Ophthalmology, Pittsburgh University School of Medicine, Pittsburgh, PA, USA.
Mechelle M LewisDepartment of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Guangwei DuDepartment of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Lan KongDepartment of Public Health Sciences, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Jeffrey M SundstromDepartment of Ophthalmology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Xuemei HuangDepartment of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Esther M BowieDepartment of Ophthalmology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Penn State Milton S. Hershey Medical Center · USPennsylvania State University · USTemple University · USUniversity of Pittsburgh · US

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological RelevanceU01NS112008 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HUANG, XUEMEI, KANTHASAMY, ANUMANTHA GOUNDER · 2019 to 2023
$5.5M
PENN STATE CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033184 · NCRR · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SINOWAY, LAWRENCE I · 2011 to 2011
$4.5M
Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's DiseaseU01NS082151 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HUANG, XUEMEI · 2012 to 2016
$4.2M
Structural MRI marker(s) of Parkinson's Disease's ProgressionR01NS060722 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HUANG, XUEMEI · 2009 to 2013
$2.9M
The Striatum and Hippocampus: "Hubs" of White Matter Connections in Parkinson's Disease Cognitive DeclineF30AG067651 · NIA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI BROWN, GREGORY L · 2020 to 2024
$153k
NCATS NIH HHS UL1 TR002014NCRR NIH HHS UL1 RR033184NIA NIH HHS F30 AG067651NINDS NIH HHS R01 NS060722NINDS NIH HHS U01 NS082151NINDS NIH HHS U01 NS112008
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is marked clinically by motor symptoms and pathologically by Lewy bodies and dopamine neuron loss in the substantia nigra pars compacta (SNc). Higher iron accumulation, assessed by susceptibility MRI, also is observed as PD progresses. Recently, evidence has suggested that PD affects the retina.

objectiveTo better understand retinal alterations in PD and their association to clinical and SNc iron-related imaging metrics.

methodsTen PD and 12 control participants (2 eyes each) from an ongoing PD imaging biomarker study underwent enhanced depth imaging optical coherence tomography evaluation. Choroidal (vascular) thickness and nerve layers were measured in 4 subregions [superior, temporal, inferior, and nasal] and at 3 foveal distances (1, 1.5, and 3 mm). These metrics were compared between PD and control groups. For significantly different metrics, their associations with clinical [levodopa equivalent daily dosage (LEDD), motor and visuospatial function] and SNc susceptibility MRI metrics [R2* and quantitative susceptibility mapping (QSM)] were explored.

resultsCompared to control participants, PD participants had a thicker choroid (p = 0.005), but no changes in nerve layers. Higher mean choroidal thickness was associated with lower LEDD (p < 0.01) and better visuospatial function (p < 0.05). Subregion analyses revealed higher choroidal thickness correlated with lower LEDD and better motor and visuospatial measures. Higher mean choroidal thickness also was associated with lower nigral iron MRI (p < 0.05).

conclusionA small cohort of PD research participants displayed higher choroidal thickness that was related to better clinical performance and less nigral pathology. These intriguing findings warrant further investigation.

Indexed as

ChoroidParkinson DiseaseHumansIronLevodopaPilot ProjectsTomography, Optical CoherenceIronLevodopaChoroidoptical coherence tomographyParkinson’s diseaseretinasusceptibility MRIvisuospatial function

Identifiers

PMID34275909
PMCPMC8530855
OpenAlexW3183258371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.